A 2‐week treatment with 5‐azacytidine improved the hypercontractility state in prostate from obese mice: Role of the nitric oxide‐cyclic guanosine monophosphate signalling pathway

Abstract

AbstractBenign prostatic hyperplasia (BPH) is characterised by increases in prostate volume and contraction. Downregulation of the nitric oxide (NO)‐cyclic guanosine monophosphate (cGMP) signalling pathway contributes to prostate dysfunctions. Previous studies in cancer cells or vessels have shown that the epigenetic mechanisms control the gene and protein expression of the enzymes involved in the production of NO and cGMP. This study is aimed to evaluate the effect of a 2‐week treatment of 5‐azacytidine (5‐AZA), a DNA‐methyltransferase inhibitor, in the prostate function of mice fed with a high‐fat diet. Functional, histological, biochemical and molecular assays were carried out. Obese mice presented greater prostate weight, α‐actin expression and contractile response induced by the α‐1adrenoceptors agonist. The relaxation induced by the NO‐donor and the protein expression of endothelial nitric oxide synthase (eNOS) and soluble guanylate cyclase (sGC) were significantly decreased in the prostate of obese mice. The treatment with 5‐AZA reverted the higher expression of α‐actin, reduced the hypercontractility state of the prostate and increased the expression of eNOS and sGC and intraprostatic levels of cGMP. When prostates from obese mice treated with 5‐AZA were incubated in vitro with inhibitors of the NOS or sGC, the inhibitory effect of 5‐AZA was reverted, therefore, showing the involvement of NO and cGMP. In conclusion, our study paves the way to develop or repurpose therapies that recover the expression of eNOS and sGC and, hence, to improve prostate function in BPH.